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randomized controlled trials (RCTs), with 19 including OS as an endpoint. Seven of 
these 19 indications had statistically significant OS data based on the most recent 
data cut included in the manufacturer’s submission to pCODR, while the remaining 
12 either did not have statistically significant OS data or the OS data were immature 
(i.e., median OS not yet reached) at the time of submission. More than half of the 12 
submissions with non-significant OS trial data allowed cross-over in the trial (n= 9) 
thereby potentially confounding the clinical benefit of the active therapy. Of the 19 
positive recommendations which had an RCT design and assessed OS as an endpoint, 
progression-free survival (PFS) was statistically significant with or without additional 
clinically or statistically significant secondary endpoints. ConClusions: This study 
highlights that positive pCODR recommendations may be made in the absence of a 
clear OS benefit, provided strong PFS and or additional endpoint data exist.
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INsIghts INto the PaN-CaNadIaN oNCology drug revew 
reCommeNdatIoNs - three years after Its INCePtIoN
Samjoo I.A.1, Grima D.T.2
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Burlington, ON, Canada
BACkground: In 2010, the permanent national oncology-specific drug review pro-
cess, pan-Canadian Oncology Drug Review (pCODR), was established to assess the 
clinical evidence and cost-effectiveness of new cancer drugs and provide recom-
mendations to the provinces (except Quebec) and territories to guide their drug 
funding decisions. oBjeCtives: This study sought to identify characteristics and 
decision patterns of the pCODR recommendations. Methods: Twenty-eight rec-
ommendations, covering 33 requested populations, publicly accessible at www.
pcodr.ca were reviewed since pCODRs operation: 13 July 2011 - 9 December 2013. 
Additional information was obtained from the www.reimbursementdecisions.com 
database. results: Of the twenty-four positive recommendations for coverage, 
three suggested a more limited patient population than the one requested. Four 
population funding requests received positive recommendations for the requested 
population without conditions. In seventeen cases, positive recommendations for 
the requested population were made conditional on improvement of cost-effective-
ness ratios. Nine negative recommendations were made due to: a) limitations in evi-
dence from phase two trials; b) modest progression-free survival, lack of statistically 
significant overall survival, lack of quality of life data and poor cost-effectiveness, 
and/or; c) unclear clinical benefit and an unacceptable cost-effectiveness model. 
Many economic reviews by pCODR included re-analyses of the cost-effectiveness 
ratios which in some cases had substantial impact on cost-effectiveness. The most 
common changes from the submitted analyses where limiting product benefit 
post-progression, time horizon reductions, or changes to post-progression mortal-
ity risk. ConClusions: Most submissions resulted in a positive funding recom-
mendation. The positive conditional pCODR recommendations support a continued 
provincial product listing agreement structure that includes rebates to lower cost-
effectiveness. The economic re-analyses of the post-progression survival benefit 
indicates a need for manufacturers to provide comprehensive consideration of 
uncertainty surrounding such benefits in the submitted cost-effectiveness analysis.
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lessoNs for adaPtIve lICeNsINg: aNalysIs of CoNdItIoNally aPProved 
ema ComPouNds, theIr reImbursemeNt status aNd regulatory/
reImbursemeNt data requIremeNts
Spearpoint P.A., Yip C.Y., Zhang W.
Pope woodhead and Associates, Cambridgeshire, UK
oBjeCtives: Understand how conditionally approved (CA) compounds in the EMA 
have performed in reimbursement assessment. Findings will inform current adap-
tive licensing initiatives. Methods: EMA EPAR reports were analysed to identify 
CA compounds from 2006−2013. HTA reports from national reimbursement authori-
ties of the UK (NICE, SMC), France (HAS), Germany (G-BA) and Italy (AIFA) were also 
analysed to understand reimbursement status of these products. results: 20 CA 
compounds were identified: 11 with current CA status, 7 fully approved and 2 with-
drawn. Approval was based upon strength of clinical data from PII/PIII studies. In 
France, 86% of CA indications were reimbursed, most with an ASMR V. In Italy, 62% 
of CA indications were reimbursed. Risk sharing agreements (RSA) were used in at 
least 38% of approvals. In Germany, approximately 50% of CA products licensed after 
AMNOG were reimbursed. In the UK, only 6 CA products received a positive NICE 
recommendation, 5 under RSAs to fulfil the cost-effectiveness criteria. CA is granted 
on limited clinical evidence. Countries using a therapeutic-benefit assessment (e.g. 
France) reimbursed more CA compounds than cost-effectiveness (CE) driven coun-
tries (e.g. UK). RSA is a key tool to win reimbursement in cost-effectiveness countries 
where high ICER thresholds impeded reimbursement (Bosutinib) or insufficient clini-
cal data (Pixantrone). Positive reimbursement decisions were driven by robust clinical 
data in orphan or small indications with limited therapies. Strategies employed by 
companies to overcome payer concerns include: 1) Initial restriction of compound 
approval to small high unmet need subpopulations; 2) Performance or financial risk 
sharing arrangements; 3) On-going evidence development plans. ConClusions: 
Reimbursement outcomes for CA compounds are variable across the EU. This is due 
to either clinical or economic uncertainties from evidence produced. To deal with 
these uncertainties, agreed mechanisms for continual evidence development and RSA 
implementations should be incorporated into on-going adaptive licensing initiatives.
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oBjeCtives: The objective of this study is to compare the HTA decisions of oncology 
products in France and Germany and provide insight into the most important asset 
value attributes that characterise a positive appraisal in these markets. Methods: 
We analysed the G-BA and the HAS assessments of 11 oncology products published 
conducted in health maintenance organizations were more likely to have a PSA-
screening, compared to physician group settings. General practitioners were more 
likely to receive PSA-screening compared to other types of specialists. Interactions 
between race and insurance type were not significant. ConClusions: Hispanics 
and individuals insured by Medicaid are less likely to receive PSA-screening dur-
ing an ambulatory care office-visit for a PHE. Efforts to improve access to cancer-
screening services are warranted for these groups. It is necessary to consider the 
differential impact of PCa-screening policies on medically underserved populations.
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CaNCer Care Costs treNd IN the uNIted states: fINdINgs from the 
medICal exPeNdIture PaNel survey 2008-2011
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oBjeCtives: To estimate the annual financial burden of cancer care in the 
United States and to study the effects of cancer on total health care of the coun-
try. Methods: Direct medical cancer care costs of for the years 2008-2011 were 
estimated using the household component of the Medical Expenditure Panel Survey 
(MEPS), a nationally representative survey that includes self-reported health care 
utilization and expenditures for the US civilian non-institutionalized population. 
The likelihood of having a cancer diagnosis by age, race and insurance status and 
other variables were also assessed. results: Aggregate cost of cancer in the US 
increased from $183 billion in 2008 to $236 billion in 2011. While total out-of-pocket 
(OOP) costs per cancer case decreased from $1,419.43 in 2008 to $1,254.77 in 2011, 
total cost per-case increased from $10,461.66 to $12,583.69 over 2008 to 2011. The 
OOP and total medical care expenditures per case in 2008 were $1,560.54 and 
$11501.69 respectively in 2011 prices using Urban Medical Consumer Price Index. 
OOP per case declined at an annual rate of 7.3% while the total direct cost increased 
at an annual rate of about 3%. Whites, females and 45-64 year olds were more likely 
to have a cancer diagnosis and most cancer care costs were covered by private insur-
ers. Geographical location was not associated with cancer diagnosis although the 
southern region has the highest concentration. ConClusions: Our study confirms 
that cancer is a significant cost driver of the US health care system. Due to expected 
increase in the number of incident cases and survival rate, total cost of cancer is 
likely to increase rapidly over the next decade. With the implementation of the 
Affordable Care Act, burden of cancer care costs on taxpayers will increase due to 
higher insurance coverage and lower OOP cost.
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aN oNlINe PatIeNt-orIeNted radIatIoN rIsk assessmeNt tool to 
ProjeCt CaNCer rIsk followINg exPosure to low–IoNIzINg radIatIoN 
IN CaNada
Zowall H., Brewer C., Deutsch A.
Zowall Consulting Inc., Westmount, QC, Canada
oBjeCtives: Increasing use of imaging procedures has raised concerns about the 
risk of cancer due to repeated exposure to low-ionizing radiation. We developed an 
online radiation risk assessment tool to project the lifetime attributable risk (LAR) 
of cancer incidence following repeated exposure to imaging procedures. Methods: 
We developed a risk projection model to assess radiation exposure from imaging 
procedures, to estimate the lifetime attributable risk (LAR) of cancer incidence and 
95% uncertainty limits (UL), according to age, gender, and imaging type. We used the 
“linear no-threshold” models (extrapolation of risk associated with high-dose ion-
izing radiation to low-dose exposure). The model has been adjusted using Canadian 
data to reflect the Canadian population. results: Selected simulation results are 
presented. The LAR of cancer incidence for a 50 and 70 year old male, exposed to 
a single coronary angiogram is 11 (95% UL: 6-22) and 6 (3-12) per 10,000 exposed, 
respectively. As the number of coronary angiograms increased from one to five over 
time, the cancer risk increased to 54 (27-106) and 26 (14-52) per 10,000, respectively. 
As age increases the excess lifetime risk of cancer decreases. The excess lifetime risk 
of cancer is higher for females than for males. The LAR of cancer for a 70 year old 
male and female, exposed to a computed tomography (CT) for suspected stroke is 4 
(2-8) and 5 (3-10) per 10,000, respectively. As the number of CT scans increased from 
one to five, the total risk of cancer increased to 17 (8-33) and 23 (12-43) per 10,000, 
respectively. ConClusions: Patients are rarely aware of radiation risk. Physicians 
often underestimate the magnitude of radiation doses arising from imaging proce-
dures. An online, interactive model might facilitate the decision making process, 
leading to more informed decisions and improved clinical outcomes.
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oBjeCtives: Overall survival (OS) data for cancer products is an important end-
point to payers. This study sought to examine (1) what proportion of positive reim-
bursement recommendations by the pan-Canadian Oncology Drug Review (pCODR) 
occurred despite unavailable statistically significant overall survival data, and (2) 
the proportion of negative recommendations that noted a lack of overall survival 
data as a contributing factor. Methods: Recommendations publicly accessible at 
www.pcodr.ca and reimbursementdecisions.com were reviewed for the period 13 July 
2011 – 9 December 2013. results: During this time period, 28 submissions contain-
ing 32 oncology-specific indications were deliberated on by the pCODR committee. 
Of the eight indications that received a negative recommendation, only one had 
statistically significant overall- and progression-free survival data. A total of 24 indi-
cations received positive recommendations. Of these, two were based on single-arm 
Phase II clinical trials. The remaining 22 positive recommendations were based on 
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since January 1st, 2011.The correlation coefficient was calculated to assess the linear 
correlation of the additional clinical benefit of an oncology product evaluated by the 
G-BA and the HAS, both measured by an arbitrary score scale from 1 (best outcome) 
to 5 (worst outcome). The G-BA score was taken from the “added benefit” rating, and 
the HAS score was determined by the ASMR rating. The additional clinical benefit is 
determined by the clinical data (efficacy, safety and QoL) provided in both GER and 
FRA. The correlation coefficient between the incremental OS benefit and the HTA 
appraisal outcome in each market was also calculated. results: The correlation 
coefficient of HTA decisions by the G-BA and the HAS for oncology products is 0.73. 
In Germany, the magnitude of incremental OS benefit negatively correlates with 
the G-BA score (correlation coefficient = -0.83). Similar results were also observed 
in France, where the correlation coefficient between the incremental OS benefit 
and the HAS score was -0.66. Interestingly, the G-BA score forms clear “steps” that 
highly correlate with the incremental OS benefit based on our empirical analysis. 
To “step up” from score 3 to score 2, an incremental OS benefit of 3 months appears 
to serve as a threshold. ConClusions: The negative linear correlation between 
the incremental OS benefit and the HTA rating in GER and FRA suggests that the 
additional clinical benefit, especially the incremental OS benefit is a major factor 
in determining the HTA outcome in GER and FRA.
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ComParIsoN of oNCology theraPy reImbursemeNt reCommeNdatIoNs 
made by health teChNology assessmeNt ageNCIes IN australIa, 
CaNada, swedeN, aNd uNIted kINgdom
Samjoo I.A.1, Grima D.T.2
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BACkground: Health technology assessment (HTA) agencies summarize infor-
mation about the medical, social, economic and ethical issues related to the use 
of health technologies in a systematic, transparent, unbiased, and robust manner. 
Several global organizations exist to provide guidance based on clinical effective-
ness, safety, and cost-effectiveness relative to alternative technologies. oBjeCtives: 
We compared recommendations made by the pan-Canadian Oncology Drug 
Review (pCODR) to other HTA agencies. Methods: Publicly accessible recom-
mendations were reviewed: Australia (Pharmaceutical Benefits Advisory Committee 
(PBAC), www.pbs.gov.au), Canada (pCODR, www.pcodr.ca), Sweden (Dental and 
Pharmaceutical Benefits Agency (TLV), www.tlv.se) and UK (National Institute for 
Health and Care Excellence (NICE), www.nice.org.uk). Additional information was 
obtained from the www.reimbursementdecisions.com database. results: pCODR 
had thirteen product reviews in common with PBAC, six with TLV, and thirteen with 
NICE. Overall, pCODR unlike the other agencies, was most likely to provide a positive 
recommendation, albeit, conditional on improvement of cost-effectiveness. In gen-
eral, negative recommendations made by pCODR based on clinical concerns were 
often mirrored by the other agencies. Similarly, findings by pCODR of positive clini-
cal benefit but with concerns over cost-effectiveness were often reciprocated by the 
other agencies in conditional positive recommendations (i.e., price reductions or risk 
sharing) or by negative recommendations due to cost-effectiveness. ConClusions: 
The recommendations by these agencies reflected significant agreement regarding 
overall clinical and economic benefit. Although discordance in recommendation 
wording between agencies was noted, these likely reflected process and funding dif-
ferences rather than a difference in the perceived product value. pCODR differs from 
other agencies in its clear distinction between evidence review and funding negotia-
tions. As such, pCODR can positively recommend a product with acceptable clinical 
value conditional on improved cost-effectiveness without specifying the degree of 
price reduction needed or negotiating such discounts. This creates an environment 
that favours early global launch in Canada without delays for price negotiation.
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the CaNCer laNdsCaPe IN brazIl: a retrosPeCtIve aNalysIs of 
brazIlIaN NatIoNal INstItute of CaNCer PatIeNt regIstry database 
(rhC-INCa)
Tsuchiya C.T., Maximo M.F.M., Gonçalves T.M.
Roche Brazil, São Paulo, Brazil
oBjeCtives: Cancer is the second lead cause of death in Brazil, with growing social 
and economic burden. According to Brazilian National Institute of Cancer/INCA, 
576.580 new cases are expected in 2014. This study aimed better understand oncol-
ogy landscape in Brazil using a real-world data source. Methods: Data reported 
from 2009-2013 was taken from RHC-INCA – an open national patient registry data-
base – for the following cancers: gastric (GC/ICD16); colorectal (CRC/ICD18-21); lung 
(LC/ICD33-34); breast (BC/ICD50); cervical (CC/ICD53) and ovarian (OC/ICD56). Only 
adult patients with TNM classification at diagnosis were included. Records labeled 
as ‘not informed’ or ‘not applicable’ were excluded. This study assessed distribution 
of those cancers according to gender; age group; stage at diagnosis for all patients; 
treatment choice and 1-year outcomes in stage IV patients with non-recorded previ-
ous treatment. results: Gender (male/female): GC–65.2%/34.8%; CRC–48.3%/51.7%; 
LC–62.2%/37.8%; BC–1.3%/98.7%. Highest frequency ages: males GC–60-74 years; 
CRC–55-69 years; LC–55-74 years; females GC–55-69 years; CRC–55-69 years; LC–55-
69 years; BC–45-59 years; CC–35-49 years; OC–45-59 years. Stage at diagnosis (0/I/
II/III/IV): GC–0.3%/10.7%/13.9%/24.8%/50.3%; CRC–0.6%/8.7%/29.5%/35.5%/25.7%; 
LC–0.1%/5.3%/6.2%/37.0%/51.4%; BC–3.0%/19.1%/36.8%/32.2%/8.8%; CC–17.5%/1
5.6%/26.3%/34.2%/6.3%; OC–0.0%/25.0%/8.5%/41.9%/24.6%. Regions with highest 
frequency of advanced cases (stages III/IV): GC–North(83.3%); CRC–South(65.1%); 
North(64.6%); LC–North(91.6%) and Northeast(91.1%); BC–North(52.2%) and 
West Center(51.6%); CC–South(49.3%) and North(45.8%); OC–South(69.9%); 
Northeast(67.3%). Stage IV treatment choice (chemotherapy alone or combined 
with another procedure/non-chemotherapy procedures): GC–73.4%/26.6%; CRC–
81.3%/18.7%; LC–75.1%/24.9%; BC–76.6%/23.4%; CC–63.5%/36.5%; OC–83.5%/16.5%. 
1-year outcomes (remission or controlled disease/progression, therapy unfeasibil-
ity or death): GC–26.9%/73.1%; CRC–34.3%/65.7%; LC–22.7%/77.3%; BC–38.4%/61.6%; 
CC–34.6%/65.4%; OC–35.1%/64.9%. ConClusions: Results evidence epidemiological 
differences between each type of cancer and amongst country regions. Regarding 
metastatic disease the majority of treatment strategies include chemotherapy; 
furthermore outcomes are poor with less than 40% of patients in remission or 
controlled disease after first year of treatment. The study had limitation regarding 
that São Paulo state data are not included in RHC-INCA.
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NadIa® Psa sloPe ImPaCts urologIsts’ reCommeNdatIoNs for 
adjuvaNt radIotheraPy for Prostate CaNCer PatIeNts wIth hIgh-
rIsk Pathology followINg radICal ProstateCtomy
Reynolds M.A1, Moul J.W.2, McDermed J.1
1Beckman Coulter, Carlsbad, CA, USA, 2Duke University School of Medicine, Durham, NC, USA
oBjeCtives: To assess the impact on medical decision-making by an in-vitro diag-
nostic test that predicts the risk of clinically recurrent prostate cancer following 
prostatectomy. Methods: ProsVue™ is an FDA-cleared prognostic test that meas-
ures the linear slope of 3 ultrasensitive prostate-specific antigen levels over time. 
In the 510(k) clinical study, ProsVue was the strongest independent predictor of 
clinically recurrent prostate cancer in a 304-man cohort study. However, its clini-
cal utility in adjuvant treatment decision-making has not yet been demonstrated. 
We prospectively enrolled men treated by radical prostatectomy in a multicenter, 
IRB-approved clinical trial. At postsurgical followup, urologist investigators (N= 17) 
stratified each of their patients into a low, intermediate or high risk group for cancer 
recurrence based on clinicopathologic findings and documented their initial treat-
ment plan. We employed the CAPRA-S postprostatectomy nomogram to standardize 
risk assessments across the investigative sites. After a patient’s ProsVue result was 
reported, urologists recorded whether or not the patient’s initial treatment plan was 
changed. The proportion of cases referred for secondary treatment before and after 
ProsVue and the significance of the difference was determined. results: Of 225 
men reported; 128 (56.9%) were stratified into intermediate and high CAPRA-S risk 
groups. Investigators reported that they would have referred 41/128 (32.0%) at-risk 
men for adjuvant radiotherapy without ProsVue information. After results were 
known, investigators referred only 15/128 (11.7%) men. The difference in proportions 
(-20.3%, 95% confidence interval [CI] -29.9 to -10.3%) is significant (p < 0.0001). Odds 
of a referral after the ProsVue result was reported was significantly reduced (Odds 
Ratio = 0.28, 95% CI 0.15 to 0.54, p < 0.0001). ConClusions: ProsVue has significant 
clinical utility in high-risk postprostatectomy cancer patients. A ProsVue result ≤ 2.0 
pg/mL/month significantly reduced the proportion of urologists’ recommendations 
for adjuvant radiotherapy. Followup studies are needed to demonstrate whether or 
not ProsVue utilization reduces health care costs.
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faCtors INflueNCINg use of geNe exPressIoN ProfIlINg by PhysICIaNs 
for breast CaNCer treatmeNt reCommeNdatIoNs
Issa A.M.1, Patil D.2
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oBjeCtives: Relatively little is known about physicians’ decisions to adopt and 
use GEP to aid in treatment recommendations. The objective of this study was to 
determine the association between specific characteristics of a GEP assay, Oncotype 
DX and oncologists’ intention to use this assay in making treatment recommen-
dations for breast cancer patients. Methods: A nationally representative sam-
ple of oncologists treating breast cancer patients was surveyed. Linear regression 
analysis was performed to establish the association between physicians’ per-
ceptions and intentions to use Oncotype DX. results: A total of 119 completed 
surveys were received yielding a response rate of 44.1%. Of the Oncotype DX test 
characteristics evaluated, ‘validity of the test’ (p= 0.006) and ‘use of Oncotype DX 
by fellow Oncologists’ (p= 0.0068) were significantly associated with oncologists’ 
use of the assay. Oncologists’ intention to use Oncotype DX increased consist-
ently with their perceptions about its usefulness (β = 0.222). Insurance status of 
the patients was also significantly associated with physicians’ use of Oncotype DX 
(p= 0.008). ConClusions: We report a novel application of an adapted technology 
acceptance model to understand decision-making by oncologists who treat breast 
cancer patients surrounding the use of GEP in making treatment recommendations. 
Our study provides insights into the characteristics and innovation factors of a 
particular genomic diagnostic that affect decision-making by oncologists who treat 
breast cancer patients. Our findings have implications for knowledge translation 
efforts related to molecular genomic diagnostics and to the development of future 
molecular genomic diagnostics.
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treatmeNt PatterNs aNd baselINe CharaCterIstICs of a ProsPeCtIve 
Cohort of PatIeNts wIth advaNCed NsClC treated IN real world 
CommuNIty oNCology settINgs
Walker M.S.1, Ravelo A.2, Miller P.J.1
1ACORN Research, LLC, Memphis, TN, USA, 2Genentech, Inc, South San Francisco, CA, USA
oBjeCtives: Overall objectives are to examine symptom burden and quality of life 
in prospectively accrued patients with advanced non-small cell lung cancer (NSCLC), 
treated in real world settings. The present report examines treatment patterns and 
baseline characteristics of an initial sample of 95 patients. Methods: Patients 
starting first line treatment of stage IIIB/IV NSCLC were prospectively accrued and 
consented at 30 US-based community oncology settings. Eligible patients received 
one of four regimens: A: pemetrexed with cisplatin or carboplatin; B: bevacizumab 
with chemotherapy doublet; C: chemotherapy doublet; D: bevacizumab, pemetrexed 
and carboplatin. Site staff collected baseline demographic and clinical informa-
tion, and patient-reported outcome and symptom measures at baseline and each 
office visit. Overall target enrollment is 225. results: Of 95 patients, 40 (42%) were 
accrued in Regimen A, 17 (17.9%) in Regimen B, 13 (13.7%) in Regimen C, and 25 
(26.3%) in Regimen D. Patients were 54.7% male, 87.4% Caucasian, with mean age 
64.6 (±11.7). 15.8% had impaired performance status (ECOG 2+ or equivalent), with 
